Clinical Observation of Sacubitril Valsartan Combined with Rosuvastatin in the Treatment of Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction
Objective To investigate the clinical efficacy of sacubitril valsartan combined with rosuvastatin in the treatment of atrial fibrillation and heart failure with preserved ejection fraction(HFpEF),and its effect on the levels of serum inflammatory factors and N-terminal pro-B-type natriuretic peptide(NT-proBNP),and cardiac function indexes in patients.Methods A total of 100 patients with atrial fibrillation and HFpEF admitted to the hospital from March 2021 to October 2022 were selected and randomly divided into the control group and the observation group by the random number table method,with 50 cases in each group.The patients in the two groups were treated with Rosuvastatin Calcium Tablets,on this basis,the patients in the observation group were treated with Sacubitril Valsartan Tablets.Both groups were continuously treated for 12 weeks.Results The total effective rate in the observation group was 68.00%,which was significantly higher than 48.00%in the control group(P<0.05).After treatment,the levels of high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),and NT-proBNP in the observation group were significantly lower than those in the control group(P<0.05);the levels of left ventricular end-diastolic diameter(LVEDd)and left ventricular end-systolic diameter(LVESd)in the observation group were significantly shorter than those in the control group(P<0.05),while the left ventricular ejection fraction(LVEF)and 6-minute walk test(6MWT)distance in the observation group were significantly higher than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was comparable to that in the control group(18.00%vs.28.00%,P>0.05).Conclusion Sacubitril valsartan combined with rosuvastatin has good clinical efficacy and safety in the treatment of atrial fibrillation and HFpEF,which can effectively improve the patient's cardiac function indexes,and reduce the levels of serum inflammatory factors and NT-proBNP.
sacubitril valsartanrosuvastatinatrial fibrillation and heart failure with preserved ejection fractioncardiac functionN-terminal pro-B-type natriuretic peptide
万方数据
维普
